Parvovirus B19: Its Role in Chronic Arthritis

Rheumatic Disease Clinics of North America

Volumn 35, Issue 1, 2009, Pages 95-110

  Colmegna, Ines ^a   Alberts Grill, Noah ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B19 arthropathy; B19 associated arthritis; Parvovirus B19; Pathogenic mechanisms; Persistence; Viral arthritis

Indexed keywords

AUTOANTIBODY; CYTOKINE; PHOSPHOLIPASE A2;

ANTIGEN ANTIBODY COMPLEX; ARTHROPATHY; AUTOIMMUNITY; CELLULAR IMMUNITY; CHRONIC ARTHRITIS; CLINICAL FEATURE; CYTOTOXICITY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ENZYME ACTIVITY; ERYTHEMA INFECTIOSUM; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; JUVENILE RHEUMATOID ARTHRITIS; MICROBIOLOGY; MOLECULAR DYNAMICS; NONHUMAN; PARVOVIRUS; PATHOGENESIS; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REACTIVE ARTHRITIS; RECEPTOR UPREGULATION; REVIEW; RHEUMATOID ARTHRITIS; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ARTHRITIS, INFECTIOUS; HOST-PATHOGEN INTERACTIONS; HUMANS; JOINTS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN;

EID: 65749084242     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2009.03.004     Document Type: Review

References (118)

1. Cossart Y.E., Field A.M., Cant B., et al. Parvovirus-like particles in human sera. Lancet 1 (1975) 72-73
2. Pattison J.R., Jones S.E., Hodgson J., et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1 (1981) 664-665
3. Anderson M.J., Jones S.E., Fisher-Hoch S.P., et al. Human parvovirus, the cause of erythema infectiosum (fifth disease)?. Lancet 1 (1983) 1378
4. Reid D.M., Reid T.M., Brown T., et al. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1 (1985) 422-425
5. White D.G., Woolf A.D., Mortimer P.P., et al. Human parvovirus arthropathy. Lancet 1 (1985) 419-421
6. Aslanidis S., Pyrpasopoulou A., Kontotasios K., et al. Parvovirus B19 infection and systemic lupus erythematosus: activation of an aberrant pathway?. Eur J Intern Med 19 (2008) 314-318
7. Corcoran A., and Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 53 (2004) 459-475
8. Franssila R., and Hedman K. Infection and musculoskeletal conditions: viral causes of arthritis. Best Pract Res Clin Rheumatol 20 (2006) 1139-1157
9. Heegaard E.D., and Brown K.E. Human parvovirus B19. Clin Microbiol Rev 15 (2002) 485-505
10. Kerr J.R. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis 59 (2000) 672-683
11. Lunardi C., Tinazzi E., Bason C., et al. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 8 (2008) 116-120
12. Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 70 (2003) 6-11
13. Moore T.L. Parvovirus-associated arthritis. Curr Opin Rheumatol 12 (2000) 289-294
14. Naides S.J. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 24 (1998) 375-401
15. Brown K.E., and Simmonds P. Parvoviruses and blood transfusion. Transfusion 47 (2007) 1745-1750
16. Mani B., Gerber M., Lieby P., et al. Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses. Transfusion 47 (2007) 1765-1774
17. Gallinella G., Venturoli S., Manaresi E., et al. B19 virus genome diversity: epidemiological and clinical correlations. J Clin Virol 28 (2003) 1-13
18. Corcoran A., Doyle S., Waldron D., et al. Impaired gamma interferon responses against parvovirus B19 by recently infected children. J Virol 74 (2000) 9903-9910
19. Kajigaya S., Fujii H., Field A., et al. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci USA 88 (1991) 4646-4650
20. Musiani M., Manaresi E., Gallinella G., et al. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J Med Virol 60 (2000) 347-352
21. Zuffi E., Manaresi E., Gallinella G., et al. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol 14 (2001) 151-158
22. Dorsch S., Liebisch G., Kaufmann B., et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 76 (2002) 2014-2018
23. Filippone C., Zhi N., Wong S., et al. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology 374 (2008) 444-452
24. Lu J., Zhi N., Wong S., et al. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis 193 (2006) 582-590
25. Zadori Z., Szelei J., Lacoste M.C., et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 1 (2001) 291-302
26. Ozawa K., and Young N. Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol 61 (1987) 2627-2630
27. Ballou W.R., Reed J.L., Noble W., et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 187 (2003) 675-678
28. Gareus R., Gigler A., Hemauer A., et al. Characterization of cis-acting and NS1 protein-responsive elements in the p6 promoter of parvovirus B19. J Virol 72 (1998) 609-616
29. Hsu T.C., Tzang B.S., Huang C.N., et al. Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells. Clin Exp Immunol 144 (2006) 152-157
30. Kerr J.R., Barah F., Mattey D.L., et al. Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 82 (2001) 3011-3019
31. Moffatt S., Yaegashi N., Tada K., et al. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 72 (1998) 3018-3028
32. Fu Y., Ishii K.K., Munakata Y., et al. Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol 76 (2002) 5395-5403
33. O'Shea J.J., and Murray P.J. Cytokine signaling modules in inflammatory responses. Immunity 28 (2008) 477-487
34. Croker B.A., Kiu H., and Nicholson S.E. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19 (2008) 414-422
35. Duechting A., Tschope C., Kaiser H., et al. Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J Virol 82 (2008) 7942-7952
36. Bruggeman L.A. Viral subversion mechanisms in chronic kidney disease pathogenesis. Clin J Am Soc Nephrol 2 Suppl 1 (2007) S13-S19
37. Yaegashi N., Niinuma T., Chisaka H., et al. Parvovirus B19 infection induces apoptosis of erythroid cells in vitro and in vivo. J Infect 39 (1999) 68-76
38. Tsay G.J., and Zouali M. Unscrambling the role of human parvovirus B19 signaling in systemic autoimmunity. Biochem Pharmacol 72 (2006) 1453-1459
39. Hsu T.C., Wu W.J., Chen M.C., et al. Human parvovirus B19 non-structural protein (NS1) induces apoptosis through mitochondria cell death pathway in COS-7 cells. Scand J Infect Dis 36 (2004) 570-577
40. Moffatt S., Tanaka N., Tada K., et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 70 (1996) 8485-8491
41. Raab U., Beckenlehner K., Lowin T., et al. NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp1/Sp3. Virology 293 (2002) 86-93
42. Norbeck O., Isa A., Pohlmann C., et al. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 79 (2005) 12117-12121
43. Isa A., Kasprowicz V., Norbeck O., et al. Prolonged activation of virus-specific CD8+T cells after acute B19 infection. PLoS Med 2 (2005) e343
44. Isa A., Norbeck O., Hirbod T., et al. Aberrant cellular immune responses in humans infected persistently with parvovirus B19. J Med Virol 78 (2006) 129-133
45. Harger J.H., Adler S.P., Koch W.C., et al. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol 91 (1998) 413-420
46. Eid A.J., Brown R.A., Patel R., et al. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 43 (2006) 40-48
47. Broliden K., Tolfvenstam T., and Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med 260 (2006) 285-304
48. Gillespie S.M., Cartter M.L., Asch S., et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 263 (1990) 2061-2065
49. Srivastava A., and Lu L. Replication of B19 parvovirus in highly enriched hematopoietic progenitor cells from normal human bone marrow. J Virol 62 (1988) 3059-3063
50. Brown K.E., Anderson S.M., and Young N.S. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262 (1993) 114-117
51. Brown K.E., Hibbs J.R., Gallinella G., et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 330 (1994) 1192-1196
52. Cooling L.L., Koerner T.A., and Naides S.J. Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis 172 (1995) 1198-1205
53. Wong S., Zhi N., Filippone C., et al. Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J Virol 82 (2008) 2470-2476
54. Bonsch C., Kempf C., and Ros C. Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. J Virol 82 (2008) 11784-11791
55. Weigel-Kelley K.A., Yoder M.C., Chen L., et al. Role of integrin cross-regulation in parvovirus B19 targeting. Hum Gene Ther 17 (2006) 909-920
56. Weigel-Kelley K.A., Yoder M.C., and Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 102 (2003) 3927-3933
57. Munakata Y., Saito-Ito T., Kumura-Ishii K., et al. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106 (2005) 3449-3456
58. Harbison C.E., Chiorini J.A., and Parrish C.R. The parvovirus capsid odyssey: from the cell surface to the nucleus. Trends Microbiol 16 (2008) 208-214
59. Zhi N., Mills I.P., Lu J., et al. Molecular and functional analyses of a human parvovirus B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity. J Virol 80 (2006) 5941-5950
60. Anderson M.J., Higgins P.G., Davis L.R., et al. Experimental parvoviral infection in humans. J Infect Dis 152 (1985) 257-265
61. Potter C.G., Potter A.C., Hatton C.S., et al. Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19). J Clin Invest 79 (1987) 1486-1492
62. Florea A.V., Ionescu D.N., and Melhem M.F. Parvovirus B19 infection in the immunocompromised host. Arch Pathol Lab Med 131 (2007) 799-804
63. Ergaz Z., and Ornoy A. Parvovirus B19 in pregnancy. Reprod Toxicol 21 (2006) 421-435
64. Corcoran A., Mahon B.P., and Doyle S. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1. J Infect Dis 189 (2004) 1873-1880
65. Peterlana D., Puccetti A., Corrocher R., et al. Serologic and molecular detection of human Parvovirus B19 infection. Clin Chim Acta 372 (2006) 14-23
66. Miki N.P., and Chantler J.K. Non-permissiveness of synovial membrane cells to human parvovirus B19 in vitro. J Gen Virol 73 Pt 6 (1992) 1559-1562
67. Anderson M.J., Lewis E., Kidd I.M., et al. An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg (Lond) 93 (1984) 85-93
68. Kerr J.R., Cunniffe V.S., Kelleher P., et al. Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. J Med Virol 74 (2004) 147-155
69. Luzzi G.A., Kurtz J.B., and Chapel H. Human parvovirus arthropathy and rheumatoid factor. Lancet 1 (1985) 1218
70. Sasaki T., Takahashi Y., Yoshinaga K., et al. An association between human parvovirus B-19 infection and autoantibody production. J Rheumatol 16 (1989) 708-709
71. Hannu T., Hedman K., Hedman L., et al. Frequency of recent parvovirus infection in patients examined for acute reactive arthritis. A study with combinatorial parvovirus serodiagnostics. Clin Exp Rheumatol 25 (2007) 297-300
72. Zerrak A., Bour J.B., Tavernier C., et al. Usefulness of routine hepatitis C virus, hepatitis B virus, and parvovirus B19 serology in the diagnosis of recent-onset inflammatory arthritides. Arthritis Rheum 53 (2005) 477-478
73. Dykmans B.A., Breedveld F.C., and de Vries R.R. HLA antigens in human parvovirus arthropathy. J Rheumatol 13 (1986) 1192-1193
74. Gendi N.S., Gibson K., and Wordsworth B.P. Effect of HLA type and hypocomplementaemia on the expression of parvovirus arthritis: one year follow up of an outbreak. Ann Rheum Dis 55 (1996) 63-65
75. Kerr J.R., Mattey D.L., Thomson W., et al. Association of symptomatic acute human parvovirus B19 infection with human leukocyte antigen class I and II alleles. J Infect Dis 186 (2002) 447-452
76. Isa A., Lundqvist A., Lindblom A., et al. Cytokine responses in acute and persistent human parvovirus B19 infection. Clin Exp Immunol 147 (2007) 419-425
77. Kerr J.R. Pathogenesis of parvovirus B19 infection: host gene variability, and possible means and effects of virus persistence. J Vet Med B Infect Dis Vet Public Health 52 (2005) 335-339
78. Fujinami R.S., von Herrath M.G., Christen U., et al. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 19 (2006) 80-94
79. Buyukkose M., Kozanoglu E., Basaran S., et al. Seroprevalence of parvovirus B19 in fibromyalgia syndrome. Clin Rheumatol 28 (2009) 305-309
80. Challine-Lehmann D., Mauberquez S., Pawlotsky J., et al. Parvovirus B19 and Schonlein-Henoch purpura in adults. Nephron 83 (1999) 172
81. Cohen B.J. Human parvovirus B19 infection in Kawasaki disease. Lancet 344 (1994) 59
82. Corman L.C., and Dolson D.J. Polyarteritis nodosa and parvovirus B19 infection. Lancet 339 (1992) 491
83. Ferguson P.J., Saulsbury F.T., Dowell S.F., et al. Prevalence of human parvovirus B19 infection in children with Henoch-Schonlein purpura. Arthritis Rheum 39 (1996) 880-881
84. Ferri C., Azzi A., and Magro C.M. Parvovirus B19 and systemic sclerosis. Br J Dermatol 152 (2005) 819-820
85. Grilli R., Izquierdo M.J., Farina M.C., et al. Papular-purpuric "gloves and socks" syndrome: polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J Am Acad Dermatol 41 (1999) 793-796
86. Harel L., Straussberg R., Rudich H., et al. Raynaud's phenomenon as a manifestation of parvovirus B19 infection: case reports and review of parvovirus B19 rheumatic and vasculitic syndromes. Clin Infect Dis 30 (2000) 500-503
87. Lehmann H.W., Kuhner L., Beckenlehner K., et al. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence. J Clin Virol 25 (2002) 135-143
88. Nikkari S., Mertsola J., Korvenranta H., et al. Wegener's granulomatosis and parvovirus B19 infection. Arthritis Rheum 37 (1994) 1707-1708
89. Perandones C.E., Colmegna I., and Arana R.M. Parvovirus B19: another agent associated with remitting seronegative symmetrical synovitis with pitting edema. J Rheumatol 32 (2005) 389-390
90. Ramos-Casals M., Cervera R., Garcia-Carrasco M., et al. Cytopenia and past human parvovirus B19 infection in patients with primary Sjogren's syndrome. Semin Arthritis Rheum 29 (2000) 373-378
91. Samii K., Cassinotti P., de Freudenreich J., et al. Acute bilateral carpal tunnel syndrome associated with human parvovirus B19 infection. Clin Infect Dis 22 (1996) 162-164
92. Schwarz T.F., Roggendorf M., Suschke H., et al. Human parvovirus B19 infection and juvenile chronic polyarthritis. Infection 15 (1987) 264-265
93. Staud R., and Corman L.C. Association of parvovirus B19 infection with giant cell arteritis. Clin Infect Dis 22 (1996) 1123
94. Yazici A.C., Aslan G., Baz K., et al. A high prevalence of parvovirus B19 DNA in patients with psoriasis. Arch Dermatol Res 298 (2006) 231-235
95. Chen Y.S., Chou P.H., Li S.N., et al. Parvovirus B19 infection in patients with rheumatoid arthritis in Taiwan. J Rheumatol 33 (2006) 887-891
96. Kozireva S.V., Zestkova J.V., Mikazane H.J., et al. Incidence and clinical significance of parvovirus B19 infection in patients with rheumatoid arthritis. J Rheumatol 35 (2008) 1265-1270
97. Peterlana D., Puccetti A., Beri R., et al. The presence of parvovirus B19 VP and NS1 genes in the synovium is not correlated with rheumatoid arthritis. J Rheumatol 30 (2003) 1907-1910
98. Weissbrich B., Suss-Frohlich Y., and Girschick H.J. Seroprevalence of parvovirus B19 IgG in children affected by juvenile idiopathic arthritis. Arthritis Res Ther 9 (2007) R82
99. Cohen B.J., Buckley M.M., Clewley J.P., et al. Human parvovirus infection in early rheumatoid and inflammatory arthritis. Ann Rheum Dis 45 (1986) 832-838
100. Jorgensen K.T., Wiik A., Pedersen M., et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 67 (2008) 860-866
101. Murai C., Munakata Y., Takahashi Y., et al. Rheumatoid arthritis after human parvovirus B19 infection. Ann Rheum Dis 58 (1999) 130-132
102. Ogawa E., Otaguro S., Murata M., et al. Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection. J Infect Chemother 14 (2008) 377-382
103. Lundqvist A., Isa A., Tolfvenstam T., et al. High frequency of parvovirus B19 DNA in bone marrow samples from rheumatic patients. J Clin Virol 33 (2005) 71-74
104. Mehraein Y., Lennerz C., Ehlhardt S., et al. Detection of parvovirus B19 capsid proteins in lymphocytic cells in synovial tissue of autoimmune chronic arthritis. Mod Pathol 16 (2003) 811-817
105. Saal J.G., Steidle M., Einsele H., et al. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 12 (1992) 147-151
106. Takahashi Y., Murai C., Shibata S., et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 95 (1998) 8227-8232
107. Nikkari S., Roivainen A., Hannonen P., et al. Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis 54 (1995) 597-600
108. Soderlund M., von Essen R., Haapasaari J., et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 349 (1997) 1063-1065
109. Foto F., Saag K.G., Scharosch L.L., et al. Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: evidence for B19 virus persistence. J Infect Dis 167 (1993) 744-748
110. Lundqvist A., Tolfvenstam T., Brytting M., et al. Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders. Scand J Infect Dis 31 (1999) 119-122
111. Norja P., Hokynar K., Aaltonen L.M., et al. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci USA 103 (2006) 7450-7453
112. Mitchell L.A., Leong R., and Rosenke K.A. Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy?. J Med Microbiol 50 (2001) 627-635
113. Tolfvenstam T., Lundqvist A., Levi M., et al. Mapping of B-cell epitopes on human parvovirus B19 non-structural and structural proteins. Vaccine 19 (2000) 758-763
114. Ray N.B., Nieva D.R., Seftor E.A., et al. Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts. Arthritis Rheum 44 (2001) 1582-1586
115. Takasawa N., Munakata Y., Ishii K.K., et al. Human parvovirus B19 transgenic mice become susceptible to polyarthritis. J Immunol 173 (2004) 4675-4683
116. Lunardi C., Tiso M., Borgato L., et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 28 (1998) 936-948
117. Kasprowicz V., Isa A., Tolfvenstam T., et al. Tracking of peptide-specific CD4+ T-cell responses after an acute resolving viral infection: a study of parvovirus B19. J Virol 80 (2006) 11209-11217
118. Saikawa T., Anderson S., Momoeda M., et al. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol 67 (1993) 3004-3009